Alejandro Yovine

1.0k total citations
24 papers, 732 citations indexed

About

Alejandro Yovine is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Alejandro Yovine has authored 24 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Alejandro Yovine's work include Cancer Treatment and Pharmacology (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Alejandro Yovine is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Alejandro Yovine collaborates with scholars based in France, United Kingdom and United States. Alejandro Yovine's co-authors include J. L. Misset, Esteban Cvitkovic, Étienne Brain, José Jimeno, M. Riofrio, A. Taamma, Jean‐Yves Blay, Carmen Kahatt, C. Martin and Yacine Salhi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Alejandro Yovine

24 papers receiving 716 citations

Peers

Alejandro Yovine
M. Riofrio France
Kirsten Leu United States
Tamara Shenkier Canada
H.T. Mouridsen Denmark
Ewa Chmielowska Poland
Rodolfo Mattioli Italy
M. Varini Switzerland
Marilyn Mulay United States
Lambros Vamvakas Greece
U. Klaassen Germany
M. Riofrio France
Alejandro Yovine
Citations per year, relative to Alejandro Yovine Alejandro Yovine (= 1×) peers M. Riofrio

Countries citing papers authored by Alejandro Yovine

Since Specialization
Citations

This map shows the geographic impact of Alejandro Yovine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Yovine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Yovine more than expected).

Fields of papers citing papers by Alejandro Yovine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Yovine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Yovine. The network helps show where Alejandro Yovine may publish in the future.

Co-authorship network of co-authors of Alejandro Yovine

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Yovine. A scholar is included among the top collaborators of Alejandro Yovine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Yovine. Alejandro Yovine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Dae Ho, Bhumsuk Keam, Ken Kato, et al.. (2023). Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. Cancer Medicine. 12(15). 16066–16075. 5 indexed citations
2.
Melillo, Giovanni, Vikram K. Chand, Alejandro Yovine, Ashok Gupta, & Cristian Massacesi. (2021). Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy. 38(6). 2759–2778. 13 indexed citations
3.
Guo, Xiang, Paul Baverel, Ignacio Ferreira González, et al.. (2021). Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma. OncoImmunology. 10(1). 1898104–1898104. 10 indexed citations
4.
Tan, Tze Heng, Sriram Sridhar, Helen K. Angell, et al.. (2020). 269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer. SHILAP Revista de lepidopterología. A165–A166. 1 indexed citations
5.
Guo, Xiang, Ignacio Ferreira González, Nassim Morsli, et al.. (2020). Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.. Journal of Clinical Oncology. 38(15_suppl). 6549–6549. 2 indexed citations
6.
7.
Salazar, Ramón, Ruth Plummer, Ana Oaknin, et al.. (2010). Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 29(6). 1406–1413. 11 indexed citations
8.
Herzog, Thomas J., J. B. Vermorken, Éric Pujade-Lauraine, et al.. (2009). Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. Journal of Clinical Oncology. 27(15_suppl). 5550–5550. 6 indexed citations
9.
Bruce, Justine Y., Begoña de las Heras, Alejandro Yovine, et al.. (2008). Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. Journal of Clinical Oncology. 26(15_suppl). 2513–2513. 7 indexed citations
10.
Soria, Jean‐Charles, et al.. (2007). QTc Monitoring During a Phase I Study. American Journal of Clinical Oncology. 30(2). 106–112. 6 indexed citations
11.
Viens, Patrice, Thierry Petit, Alejandro Yovine, et al.. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annals of Oncology. 17(3). 429–436. 31 indexed citations
12.
Delozier, T., Jean‐Paul Guastalla, Alejandro Yovine, et al.. (2006). A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anti-Cancer Drugs. 17(9). 1067–1073. 12 indexed citations
13.
Zelek, Laurent, Alejandro Yovine, Étienne Brain, et al.. (2006). A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. British Journal of Cancer. 94(11). 1610–1614. 77 indexed citations
14.
Petit, Thierry, Abdellatif Benider, Alejandro Yovine, et al.. (2006). Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anti-Cancer Drugs. 17(3). 337–343. 23 indexed citations
15.
Raymond, Éric, Svein Dueland, Michael Lind, et al.. (2005). Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. Cancer Research. 65. 936–936. 2 indexed citations
16.
Yovine, Alejandro, M. Riofrio, Jean‐Yves Blay, et al.. (2004). Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients. Journal of Clinical Oncology. 22(5). 890–899. 261 indexed citations
17.
Viens, Patrice, Thomas Petit, Alejandro Yovine, et al.. (2004). Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results. Journal of Clinical Oncology. 22(14_suppl). 5023–5023. 6 indexed citations
18.
19.
Goldwasser, François, Marine Gross‐Goupil, Jean‐Marie Tigaud, et al.. (2000). Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Annals of Oncology. 11(11). 1463–1470. 46 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Riofrio Breakdown of academic impact, for papers by Kirsten Leu Breakdown of academic impact, for papers by Tamara Shenkier Breakdown of academic impact, for papers by H.T. Mouridsen Breakdown of academic impact, for papers by Ewa Chmielowska Breakdown of academic impact, for papers by Rodolfo Mattioli Breakdown of academic impact, for papers by M. Varini Breakdown of academic impact, for papers by Marilyn Mulay Breakdown of academic impact, for papers by Lambros Vamvakas Breakdown of academic impact, for papers by U. Klaassen
Rankless by CCL
2026